Fig. 3

ML355 reduced HCC recurrence by inhibiting ALOX12–12-HETE pathway. a, b 12-HETE in serum and in cell supernatant were measured. (n = 4–5 per group) c, d. Mice was pretreated with ML355 (3 mg/kg body weight, MCE, USA) at 1 h before ischemia. Representative images and HRA of HCC recurrence in HFD mice pretreated with ML355 or PBS followed by IRI and inoculated with Hepa1–6 cells. Scale bars, 1 cm. (n = 3–4 per group) e. Representative H&E staining of liver sections of HCC recurrence in HFD mice pretreated with ML355 or PBS followed by IRI and inoculated with Hepa1–6 cells. Scale bars, 200 μm. f. qPCR analysis of Bv8, S100a8, S100a9 and VEGF in HFD mice pretreated with ML355 or PBS followed by IRI. (n = 4–5 per group) g. qPCR analysis of Bv8, S100a8, S100a9 and VEGF in AML12 cells pretreated with ML355 or PBS and stimulated with PA followed by HR. (n = 4–5 per group). Data are mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t- test